Emergent BioSolutions Inc. (EBS)

↓ Download CSV

CIK 0001367644 · NYSE · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Emergent BioSolutions Inc. reported revenue of $742.90M, down 28.8% from the prior year. The company was profitable, with a net margin of 7.1%. It held $1.32B in total assets against $796.00M in total liabilities.

Key ratios (FY2025)

13.5%
Operating margin
7.1%
Net margin
10.1%
Return on equity
-28.8%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$742.90M$1.04B$1.05B$1.12B$1.77B$1.58B$1.11B
Cost of Revenue$326.20M$681.30M$705.40M$693.10M$748.10M$537.00M$433.50M$322.30M$187.70M$126.30M
Gross Profit$317.60M$383.00M$891.30M$925.20M
Operating Income$100.10M-$108.70M-$726.40M-$170.00M$341.40M$438.50M$114.10M$89.80M$124.30M$105.50M
Net Income$52.60M-$190.60M-$760.50M-$211.60M$219.50M$305.80M$54.50M$62.70M$82.60M$51.80M
EPS (Diluted)$0.93$-3.60$-14.85$-4.22$4.06$5.68$1.04$1.22$1.71$1.13
Total Assets$1.32B$1.39B$1.82B$3.17B$2.96B$2.88B$2.33B$2.23B$1.07B$970.11M
Total Liabilities$796.00M$906.90M$1.17B$1.78B$1.35B$1.44B$1.24B$1.22B$157.90M$373.91M
Shareholders' Equity$522.60M$482.80M$649.30M$1.39B$1.61B$1.45B$1.09B$1.01B$912.30M$596.20M
Cash & Equivalents$205.40M$99.50M$111.70M$642.60M$576.10M$621.30M$167.80M$112.20M$178.30M$271.50M
Operating Cash Flow$170.60M$58.70M-$206.30M-$34.10M$320.20M$536.90M$188.00M$41.80M$208.10M$54.60M
Capital Expenditures$13.80M$22.90M$51.60M$115.80M$224.10M$141.90M$86.90M$72.10M$54.80M$76.20M
Shares Outstanding56.70M53.00M51.20M50.10M54.10M53.80M52.40M51.40M50.30M49.30M